• 1
    Thomas RH. Hypercoagulability states. Arch Intern Med 2001; 161: 24339.
  • 2
    Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 101927.
  • 3
    Khamashta MA, Ruiz-Irastorza G. Management of thrombosis in antiphospholipid syndrome. In: KhamashtaMA, editor. Hughes syndrome. 2nd ed. London: Springer-Verlag; 2006. p. 54754.
  • 4
    Brunner HI, Chan WS, Ginsberg JS, Feldman BM. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome: result of a decision analysis. J Rheumatol 2002; 29: 490501.
  • 5
    Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl 3: 401S28S.
  • 6
    Brey RL, Chapman J, Levine SR, Ruiz-Irastorza G, Derksen RH, Khamashta M, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003; 12: 50813.
  • 7
    Meroni PL, Moia M, Derksen RH, Tincani A, McIntyre JA, Arnout JM, et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003; 12: 5047.
  • 8
    Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 10507.
  • 9
    Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome: treatment controversies. Future Rheumatol 2006; 1: 34553.
  • 10
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 11
    Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129: 17481.
  • 12
    Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 3038.
  • 13
    Khamashta MA, Cuadrado MJ, Mujic F, Taub N, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 9937.
  • 14
    Munoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tassies D, Espinosa G, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999; 29: 18290.
  • 15
    Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 11649.
  • 16
    Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsch J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 2003; 349: 11338.
  • 17
    Ames PR, Ciampa A, Margaglione M, Scenna G, Iannaccone L, Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005; 93: 6949.
  • 18
    Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 84853.
  • 19
    Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffat K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 10: 368591.
  • 20
    Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation [letter]. Thromb Haemost 1996; 75: 859.
  • 21
    Schulman S, Svenungsson E, Granqvist S, and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 3328.
  • 22
    Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al, and the APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 57684.
  • 23
    Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 15607.
  • 24
    Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 68992.
  • 25
    Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 21018.
  • 26
    Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism [letter]. Thromb Haemost 1997; 77: 2212.
  • 27
    Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 13741.
  • 28
    Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 144451.
  • 29
    Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 7782.
  • 30
    Pierangeli S. Anticardiolipin testing. In: KhamashtaMA, editor. Hughes syndrome. 2nd ed. London: Springer-Verlag; 2006. p. 27590.
  • 31
    Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 38790.
  • 32
    Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 41528.
  • 33
    Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Garmendia M, Erdozain JG, Villar I, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007; 16: 8106.
  • 34
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 35
    Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl 3: 287S310S.
  • 36
    Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 4238.
  • 37
    Ruiz-Irastorza G, Kahmashta MA. Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology (Oxford) 2005; 44: 9714.